Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation
NCT ID: NCT02264938
Last Updated: 2014-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
35 participants
INTERVENTIONAL
2013-01-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antioxidant Systems and Age-Related Macular Degeneration
NCT00668213
Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.
NCT03919019
Macula Evolution in Patients With AMD Taking Oral Food Supplementation
NCT04778436
The Influence of Lutein Supplements on Age-related Macular Degeneration
NCT01042860
Omega-3-fatty Acids on Age-related Macular
NCT01258335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observation
Patients with AREDS category 2 and 3 AMD are observed during 1 year
No interventions assigned to this group
Antioxidant
Patients with AREDS category 2 and 3 AMD are enrolled to take daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid \[DHA\] 540mg + eicosapentaenoic acid \[EPA\] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg) during 1 year.
Antioxidant
Oral supplemmentation with antioxidants
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antioxidant
Oral supplemmentation with antioxidants
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* other ophthalmological diseases
* currently on antioxidant supplementation
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Germans Trias i Pujol Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xavier Valldeperas
MD, PhD, FEBO
References
Explore related publications, articles, or registry entries linked to this study.
Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023 Sep 13;9(9):CD000254. doi: 10.1002/14651858.CD000254.pub5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-11-112
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.